What is CDR-Life?
CDR-Life is a specialized biotherapeutics enterprise dedicated to the development of novel immunotherapies designed to harness the immune system against tumor cells. At the core of its operations is a sophisticated antibody platform that targets intracellular tumor antigens presented on the major histocompatibility complex (MHC). This technical capability allows for the creation of highly specific T cell engagers, which are essential for addressing high-need solid tumor indications. Beyond its internal pipeline, the company has demonstrated commercial validation through a strategic collaboration and licensing agreement with Boehringer Ingelheim, focusing on antibody fragment therapies for macular degeneration. Led by a team of seasoned biologics inventors and pharmaceutical developers, CDR-Life bridges the gap between complex molecular biology and clinical-stage drug development.
How much funding has CDR-Life raised?
CDR-Life has raised a total of $76M across 1 funding round:
Series A
$76M
Series A (2022): $76M with participation from Omega Fund Management, RA Capital Management, and Jeito
Key Investors in CDR-Life
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
Jeito
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation.
Omega Fund Management
Omega Fund Management is a venture capital firm specializing in early-stage life sciences and biotechnology investments, focusing on companies with transformative potential in human health.
What's next for CDR-Life?
With the infusion of this recent capital, CDR-Life is poised to accelerate its clinical development trajectory. The strategic focus will likely center on advancing its portfolio of tumor-specific T cell engagers through rigorous preclinical and early-stage clinical trials. As the company scales its operations, the emphasis will remain on validating its MHC-targeting platform in human subjects, potentially unlocking new therapeutic avenues for patients with limited treatment options. Furthermore, the firm is expected to continue leveraging its existing pharmaceutical partnerships to diversify its therapeutic reach, ensuring that its proprietary technology remains at the forefront of the biopharmaceutical industry's efforts to combat complex, high-need diseases.
See full CDR-Life company page
